These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 23271795)

  • 21. An indirect comparison of dabigatran, rivaroxaban and apixaban for atrial fibrillation.
    Mantha S; Ansell J
    Thromb Haemost; 2012 Sep; 108(3):476-84. PubMed ID: 22740145
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [The results of the RE-lY study promise more effective, safer and easier prevention of embolic complications in patients with non-valvular atrial fibrillation].
    Vojácek J
    Vnitr Lek; 2009 Nov; 55(11):1085-8. PubMed ID: 20017441
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Another novel oral anticoagulant matches warfarin.
    Mitka M
    JAMA; 2014 Jan; 311(3):233-4. PubMed ID: 24430308
    [No Abstract]   [Full Text] [Related]  

  • 24. Dabigatran etexilate for thromboembolic prophylaxis in non-valvular atrial fibrillation: the RE-LY study and substudies with commentary.
    Waks JW; Zimetbaum PJ
    Expert Rev Cardiovasc Ther; 2013 Nov; 11(11):1461-71. PubMed ID: 24147516
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Dabigatran etexilate: a review of its use in the prevention of stroke and systemic embolism in patients with atrial fibrillation.
    Garnock-Jones KP
    Am J Cardiovasc Drugs; 2011; 11(1):57-72. PubMed ID: 21265583
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A new era of antithrombotic therapy in patients with atrial fibrillation.
    Golwala H; Dib C; Tafur A; Abu-Fadel MS
    Am J Med Sci; 2012 Aug; 344(2):128-35. PubMed ID: 22245946
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Does warfarin for stroke thromboprophylaxis protect against MI in atrial fibrillation patients?
    Lip GY; Lane DA
    Am J Med; 2010 Sep; 123(9):785-9. PubMed ID: 20655037
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Efficacy and safety of dabigatran compared to warfarin in patients with paroxysmal, persistent, and permanent atrial fibrillation: results from the RE-LY (Randomized Evaluation of Long-Term Anticoagulation Therapy) study.
    Flaker G; Ezekowitz M; Yusuf S; Wallentin L; Noack H; Brueckmann M; Reilly P; Hohnloser SH; Connolly S
    J Am Coll Cardiol; 2012 Feb; 59(9):854-5. PubMed ID: 22361407
    [No Abstract]   [Full Text] [Related]  

  • 29. Current and future alternatives to warfarin for the prevention of stroke in atrial fibrillation.
    Bommer WJ
    Crit Pathw Cardiol; 2012 Jun; 11(2):45-54. PubMed ID: 22595814
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Dabigatran etexilate versus warfarin as the oral anticoagulant of choice? A review of clinical data.
    Ma TK; Yan BP; Lam YY
    Pharmacol Ther; 2011 Feb; 129(2):185-94. PubMed ID: 20920530
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Switching between oral anticoagulants.
    Strasser KM; Qasem A; Madhusudhana S
    Hosp Pract (1995); 2014 Aug; 42(3):68-74. PubMed ID: 25255408
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cost-effectiveness of dabigatran etexilate for the prevention of stroke and systemic embolism in atrial fibrillation in Taiwan.
    Chang CH; Yang YH; Chen JH; Lin LJ
    Thromb Res; 2014 May; 133(5):782-9. PubMed ID: 24642004
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Efficacy and safety of dabigatran etexilate and warfarin in "real-world" patients with atrial fibrillation: a prospective nationwide cohort study.
    Larsen TB; Rasmussen LH; Skjøth F; Due KM; Callréus T; Rosenzweig M; Lip GY
    J Am Coll Cardiol; 2013 Jun; 61(22):2264-73. PubMed ID: 23562920
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Indirect comparisons of new oral anticoagulant drugs for efficacy and safety when used for stroke prevention in atrial fibrillation.
    Lip GY; Larsen TB; Skjøth F; Rasmussen LH
    J Am Coll Cardiol; 2012 Aug; 60(8):738-46. PubMed ID: 22575324
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Dabigatran etexilate in people with atrial fibrillation.
    Raju NC; Hankey GJ
    BMJ; 2010 Jul; 341():c3784. PubMed ID: 20671015
    [No Abstract]   [Full Text] [Related]  

  • 36. Dabigatran (Pradaxa). An alternative to warfarin (Coumadin) is approved to help treat patients with atrial fibrillation.
    Heart Advis; 2011 Apr; 14(4):6. PubMed ID: 22977933
    [No Abstract]   [Full Text] [Related]  

  • 37. Use of dabigatran to prevent stroke in patients with atrial fibrillation.
    Mooney T
    Nurs Stand; 2013 Mar 6-12; 27(27):35-41. PubMed ID: 23556305
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Dabigatran in clinical practice.
    Nagarakanti R; Ellis CR
    Clin Ther; 2012 Oct; 34(10):2051-60. PubMed ID: 23031622
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Alternatives to warfarin for stroke prevention in patients with nonvalvular atrial fibrillation: a look back at the state of the field in 2012.
    Truffa AA; Lopes RD; Newby LK
    Postgrad Med; 2013 Mar; 125(2):146-57. PubMed ID: 23816780
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Changing practice of anticoagulation: will target-specific anticoagulants replace warfarin?
    Arepally GM; Ortel TL
    Annu Rev Med; 2015; 66():241-53. PubMed ID: 25587651
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.